Over the years we have seen many discussions about storing levothyroxine.
◾ Should we refrigerate it?
◾ Can we freeze it?
◾ Does it make any difference if it is in a blister pack or "loose" in a pot?
◾ Can we put it into dosettes or other ways of organising medicines?
We have also seen questions over the difference between "levothyroxine sodium anhydrous" identified as an ingredient in some products. Indeed, that has cropped up often enough for me to have written a document which tries to explain how I see the issue:
dropbox.com/s/pqwuga75fxvkd...
I still don't have sufficient understanding to fully answer the questions! But I do appreciate that we need to think about what we do and not make assumptions.
This paper points out that there are issues. Many have realised that humidity affects levothyroxine. But fewer see that dryness might be just as big an issue.
Partial Dehydration of Levothyroxine Sodium Pentahydrate in a Drug Product Environment: Structural Insights into Stability
Navpreet Kaur 1 , Victor G Young Jr 2 , Yongchao Su 3 , Raj Suryanarayanan 1
Affiliations
• PMID: 32960611
• DOI: 10.1021/acs.molpharmaceut.0c00661
Abstract
Levothyroxine sodium pentahydrate (LSP; C15H10I4NNaO4·5H2O) gradually loses one molecule of water of crystallization as the water vapor pressure is decreased from 90% to 15% RH (40 °C), a behavior characteristic of nonstoichiometric hydrates. LSP loses four molecules of water of crystallization to form levothyroxine sodium monohydrate (LSM; C15H10I4NNaO4·H2O) under realistic storage conditions (40 °C/0% RH for 3 h). The crystal structure of LSP was determined following which the specimen was partially dehydrated in situ to form LSM. The crystal structure of LSM provided insight into its potential for high reactivity. Thus, its presence in a drug product is undesirable. In LSP-oxalic acid mixtures stored in a hermetic container at 40 °C, there was moisture transfer from drug to excipient. Synchrotron X-ray diffractometry revealed dehydration of LSP resulting in LSM, while anhydrous oxalic acid transformed to its dihydrate. In formulations of LSP, chemical degradation of levothyroxine sodium may be preceded by its partial dehydration.
Keywords: chemical stability; crystal structure; drug product; levothyroxine sodium; physical form.